History | Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer | Guidance | NICE

History

A list of downloadable documents created during development.

Background information

Colon cancer (adjuvant) - capecitabine & oxaliplatin (final appraisal determination)

Colon cancer (adjuvant) - capecitabine & oxaliplatin (final appraisal determination) information
Colon cancer (adjuvant) - capecitabine & oxaliplatin (final appraisal determination) ^{PDF 130 KB} 27 February 2006

Consultee and commentator comments on Appraisal Consultation Document

Consultee and commentator comments on Appraisal Consultation Document ^{PDF 100 KB} 27 February 2006

Appraisal Consultation Document: Colon cancer (adjuvant) - capecitabine & oxaliplatin

Appraisal Consultation Document: Colon cancer (adjuvant) - capecitabine & oxaliplatin information

Overview

Overview ^{PDF 201 KB} 28 October 2005

Colon cancer (adjuvant) - capecitabine and oxaliplatin: assessment report

Colon cancer (adjuvant) - capecitabine and oxaliplatin: assessment report ^{PDF 2.11 MB} 28 October 2005

Response to Consultee Comments

Response to Consultee Comments ^{PDF 43 KB} 28 October 2005

Consultee and commentator comment on the assessment report

Consultee and commentator comment on the assessment report
Colon Cancer Concern ^{PDF 14 KB} 28 October 2005
Institute for Cancer Research ^{PDF 14 KB} 28 October 2005
NHS QIS ^{PDF 27 KB} 28 October 2005
Royal College of Nursing ^{PDF 25 KB} 28 October 2005
Royal College of Physicians ^{PDF 50 KB} 28 October 2005

Non-manufacturer submissions

Non-manufacturer submissions
British Oncology Pharmacy Association (1) ^{PDF 45 KB} 28 October 2005
British Oncology Pharmacy Association (2) ^{PDF 47 KB} 28 October 2005
CancerBACUP ^{PDF 50 KB} 28 October 2005
Cancer Concern ^{PDF 39 KB} 28 October 2005
Joint submission - Royal College of Physicians, the Royal College of Radiologists, the Association of Cancer Physicians and the Joint Collegiate Council for Oncology ^{PDF 28 KB} 28 October 2005
Royal College of Nursing ^{PDF 32 KB} 28 October 2005

Manufacturer submissions

Manufacturer submissions
Roche ^{PDF 28 KB} 28 October 2005
Roche executive summary ^{PDF 229 KB} 28 October 2005
Sanofi Aventis ^{PDF 97 KB} 28 October 2005
Sanofi Aventis updated submission - new evidence ^{PDF 161 KB} 28 October 2005
Sanofi Aventis executive summary ^{PDF 1.74 MB} 28 October 2005

Expert written personal statements

Expert written personal statements
Craven ^{PDF 31 KB} 28 October 2005
Levine ^{PDF 17 KB} 28 October 2005
Marks ^{PDF 23 KB} 28 October 2005
Sharma ^{PDF 36 KB} 28 October 2005

Final protocol

Final protocol ^{PDF 55 KB} 23 March 2005

Final scope

Final scope ^{PDF 26 KB} 27 January 2005

Summary of consultee comments on the draft scope

Summary of consultee comments on the draft scope ^{PDF 44 KB} 27 January 2005

Summary of consultee and commentator comments on provisional matrix

Summary of consultee and commentator comments on provisional matrix ^{PDF 22 KB} 27 January 2005

Archive: draft scope

Archive: draft scope ^{PDF 27 KB} 12 November 2004

Archive: provisional matrix of consultees and commentators

Archive: provisional matrix of consultees and commentators ^{PDF 29 KB} 12 November 2004